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Abstract 
Mentioning DZ-BAU2021-14 (C19H17N5O2,347.370 g/mol) developed in BAU Labs, its promising 
preliminary antitumor effect nominated it to be selected as a lead antiproliferative compound against 
colorectal cancer cell lines owing to its proved Cyclin Dependent Kinase 2 (CDK2) inhibition (Kassem 
et al., 2021). Solving many problems restricting traditional cancer therapy, nanotechnology is offering 
safety margins and targeted delivery of poorly soluble drug. The potential effect of this compound was 
combined with the advantages of nanotechnology, precisely nanocrystals to achieve better antiproliferative 
and hopeful less cytotoxic patterns. The nanocrystals DZ-BAU2021-14N were prepared by an antisolvent 
precipitation technique using Poloxamer 407 and Cremophor® RH 40 as stabilizers. The nanocrystals 
were obtained with a nanometric particle size (89.80 ± 11.2 nm) and a negative zeta potential (-32.6 ± 
0.50 mV) and were stable at 4 ± 0.5°C with no significant change in particle size or zeta potential. The 
anticancer activity of DZ-BAU2021-14 and DZ-BAU2021-14N were assessed. Their antiproliferative effects 
against colorectal cancer cell lines HCT-116 and HT-29 were studied via viability assay. In addition, their 
cytotoxic effects on non-tumorigenic cell lines NCM-460D were evaluated and respective IC50 values 
were determined. Different responses were obtained; DZ-BAU2021-14N provided lower IC50 on HCT-116 
compared to the free drug DZ-BAU2021-14 (27 and 22 µM, respectively). The safety profile of the free 
drug was reflected by its IC50 on NCM-460D of 200µM while that of drug nanocrystals showed relative 
cytotoxicity with IC50 of 33µM, and this requires further investigation to study this response. 
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Cancer is considered nowadays, a global health threat. It is the world's second leading cause of 
death, and is predicted in the coming years to be the main cause of death (Siegel et al., 2019). Cancer 
is a disease involving abnormal and uncontrolled cell growth. There are many types of cancer each 
with own set of symptoms (Kumar Shital, 2021). Despite the disease's malignancy, it is still possible 
to lower mortality rates, before invasion and progression to metastasis, by early and accurate 
diagnosis and treatment.  
In spite of the requisite advancements occurring in design and production of various anticancer 
agents over the last decades, existing and accessible therapies still have two major drawbacks; the 
lack of selectivity and targeted delivery for cancer tissues causing undesirable side effects, and the 
development of drug resistance by cancer cells making them unresponsive to standard therapy which 
is considered one of the most pressing dilemmas in cancer therapy (Alfarouk et al., 2015; Pick et al., 
2010). The absence of perfect anticancer therapies necessitates new approaches to improve quality of 
current treatments. As a result, the principle of developing targeted drugs arises as solution to this 
global problem (Fares et al., 2020).  
Colorectal Cancer (CRC) is being primarily localized within the colon and rectum (Stintzing 
et al., 2017). The annual report in United States studying the prevalence of different types of cancer 
was stating that colorectal cancer (CRC) is the third most common cancer among women and men 
(Jemal et al., 2017). Additionally, CRC is the fourth leading cause of cancer mortality in both men 
and women. CRC occurs chiefly in populations over 50 years of age though it can happen at any age 
and annual deaths around 690,000 people (Rejhová et al., 2018). More than half of CRC cases 
worldwide are registered in developed countries, with rising incidences in developing ones (Kuipers 
et al., 2015). The current treatment of CRC is based on surgery and chemotherapy. Taxol, 5-
Fluorouracil (5-FU), Doxorubicin and Roscovitine, are used to treat human colorectal cancer 
individually and/or in combination (Abaza et al., 2008).  
Roscovitine, 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (Fig. 1), 
belongs to purines family which has an imidazopyrimidine structure. Roscovitine arrests the cell cycle 
in G0, G1, S or G2/M, by directly inhibiting Cyclin Dependent Kinases (CDKs) (Cicenas et al., 2015).  
It showed antiproliferative effect on CRC cell lines HCT-116 and HT-29 with IC50 value of 12.24 




Fig.1: Antiproliferative effect of Roscovitine on HCT-116 and HT-29 
Pyrazolopyrimidine and pyrazolopyridine are considered isosteric analogs to 
imidazopyrimidine, they possess a wide variety of biological activities. They were highlighted being 
antimicrobial (Abdelmohsen & El Emary, 2014), antimalarial (Pinheiro et al., 2019), antitumor 
(Karrouchi et al., 2018), tuberculostatic (Hu et al., 2019), anti-inflammatory agents (Dennis 
Bilavendran et al., 2020) and having cardiovascular activities (Avari, 2019). They also demonstrated 
antiproliferative effect on colorectal cancer cell lines (Fig. 2). Synthesizing pyrazolo[3,4-
d]pyrimidines as anticancer agents, compound 2-((4-(benzylamino)-1H-pyrazolo[3,4-d]pyrimidin-6-
yl)amino)ethan-1-ol (1) showed high activity on colorectal cancer cell line HCT-116 with IC50 value 
of 4.5 µM (Ismail et al., 2016). 5,7-Dihydroxy-2-((4-methoxyphenyl)amino)-N-phenylpyrazolo[1,5-
a]pyrimidine-3-carboxamide) (2) showed antitumor activity against colorectal cancer cells HCT-116 
exhibiting IC50 of 58.44 ± 3.8% µg/mL equivalent to 149 ± 3.8%  µM (Hassan et al., 2017). 
1
Kassem et al.: DZ-BAU2021-14N AS NOVEL PYRAZOLOPYRIDINE NANOCRYSTALS: APPRAISAL OF ANTICANCER ACTIVITY AGAINST HCT-116 AND HT-29 COLORECTAL CANCER CELL LINES
Published by Digital Commons @ BAU, 2021
 
 
Pyrazolopyridopyrimidine analogs, designed and synthesized as hybrid scaffolds for their 
antimicrobial and antitumor potential, deliberated the promising 5-imino-3-methyl-4-phenyl-1,4,5,9-
tetrahydro-6H-pyrazolo[4',3':5,6]pyrido[2,3-d]pyrimidin-6-amine (3) being the most active 
compound against HCT-116 cell line with an IC50 value of 3.18 µM (El-Gohary et al., 2019). In 
attempts to design and synthesize antitumor agents with improved solubility and pharmacokinetic 
properties, 3-(4-(methoxymethyl)-1H-benzo[d]imidazol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-






Fig.2: Structures and IC50 of some pyrazolo-pyrimidine and -pyridine derivatives on HCT-116 cancer cell 
line 
Nanotechnology has been proved to solve some of the main problems limiting conventional 
cancer treatments, it might offer more specific delivery of therapeutics and reduction of toxic 
secondary effects. It plays a significant role in targeted delivery and release of drugs such as 
nanoparticles, dendrimers, nanoshells, liposomes, niosomes, nanocrystals, and magnetic 
nanoparticles (Alexis et al., 2008; Rajendra et al., 2018). Recently nanocrystalization technology has 
sparked a lot of interest as a way to overcome the obstacles of poorly soluble anticancer drugs. These 
nanocrystals (NSs) are colloidal dispersions of pure drug in an outer liquid phase with particle size 
ranging from 100 to 1,000 nm with a large surface area to enhance solubility and bioavailability of 
these drugs (Mohyeldin et al., 2016).  
 Mainly there are two main techniques to produce NCs; the top-down method which is based 
on size reduction of the large particles into smaller ones, and the bottom-up technologies that depend 
on the growth of small particles from individual molecules as in the antisolvent precipitation process 
(de Waard et al., 2011). The latter is a popular approach used for its simplicity and low setup cost 
(Freag et al., 2013; Saindane et al., 2013; Tian et al., 2013). 
Understanding the problems of available anticancer drugs, the role of nanocrystalization, in 
potentiating the efficacy of a new molecule, is a target.  
 In consequence, this study mainly aims to construct DZ-BAU2021-14N nanocrystals utilizing 
the antisolvent precipitation technique with the aid of two different stabilizers, and to evaluate its in-
vitro antiproliferative and cytotoxic effect in comparison to free DZ-BAU2021-14 using MTT assay 
on two colorectal cancer cell lines HCT-116 and HT-29 compared to non-tumorigenic NCM-460D. 
Establishing the average particle size and zeta potential of the prepared nanocrystals as well as 
evaluating the interaction between the molecule under investigation and the polymers in the 
nanopreparation using Fourier transform infrared spectroscopy (FT-IR) and X-ray diffraction (XRD) 
technique are considered as fundamental objectives the current study. 
 
2. MATERIALS AND METHODS 
2.1. Nanocrystal’s Formulation 
2.1.1. Materials 
 DZ-BAU2021-14 was synthesized in BAU Labs, Poloxamer 407 and Cremophor® 
RH 40 were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). All organic 
solvents were of analytical grade and purchased from Sigma-Aldrich. 
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2.1.2. Screening stabilizers for the nanoprecipitation technique 
The previous selection for the optimal stabilizer was based on the ability of these 
different stabilizers to achieve stable nanocrystals and was applied as a screening 
parameter (Mohyeldin et al., 2016). Poloxamer® 407 and Cremophor® RH40 were used 
with 0.5% w/v and 1% w/v, respectively. The selection was based on the average particle 
size and the Polydispersity Index (PDI) of the formed nanocrystals.  
 
2.1.3. Preparation of the nanocrystals 
DZ-BAU2021-14 nanocrystals were tailored by applying the antisolvent 
nanoprecipitation technique previously reported (Mohyeldin et al., 2016). Briefly, a 
saturated solution of the molecules under investigation dissolved in acetone was added to 
deionized water as the non-solvent phase, containing a suitable stabilizer at a ratio of 1:10. 
The solvent phase was added to the aqueous phase with rapid stirring at room temperature 
(25 ± 0.5°C) for 30 minutes.  
 
2.1.4.  Particle characteristics 
2.1.4.1. Physicochemical characteristics of DZ-BAU2021-14N nanocrystals 
Droplet size, zeta potential, and PDI were measured at 25 ± 2°C and 90° 
scattering angle by Zeta sizer 2000 (Malvern Instruments, UK) after dilution 
with deionized water (1:100 v/v) (Zhou et al., 2018). All measurements were 
carried out in triplicate and mean ±SD was calculated. 
 
2.1.4.2. Fourier transform infrared spectroscopy (FT-IR) 
To assess whether there is any possible interaction between the free 
drug, Poloxamer 407, Cremophor® RH 40, their physical mixture, and the 
prepared nanocrystals (after freeze-drying) an FT-IR spectrometer 
(PerkinElmer Inc., Waltham, MA USA) was used. Each sample was mixed 
with dry infrared (IR) grade of crystalline potassium bromide then compressed 
at 10 tons in a hydraulic press to form a thin disk. Each sample was scanned 
within the spectral region of 4,000 and 400 cm-1 with a resolution of 4 cm-1 
(Aguayo et al., 2018). 
 
2.1.4.3. X-ray diffraction (XRD) 
All samples were analyzed using a Siemens D-500 X-ray powder 
diffraction (XRD) device. CuKα was targeted using a voltage of 40 kV and a 
current of 30 mA during the XRD measurements and circumstances. A 
modified system of diverging and receiving as well as receiving and anti-
scattering slits of 1°, 1°, 1°, and 0.15°, respectively, was utilized. Jade 6.0 
(Materials Delta Inc.) was used for data processing. The XRD patterns were 
obtained using a step width of roughly 0.04° 2𝜃 between 5° and 50° 
(Kaviyarasu et al., 2017).  
 
2.1.4.4. Storage stability 
The physical and thermal stability was assessed by performing short-
term storage studies.  The formulated nanocrystals were stored in capped 
amber glass vials at two different temperatures (4°C and 25°C as the 
refrigerator and room temperature, respectively) for 3 months. Every month, 
the stored formulations were monitored by droplet size, zeta potential, PDI 
determination (Mehanna et al., 2020).  
2.2.  In-Vitro Cytotoxicity Study 
2.2.1. Cell lines 
Two colorectal cancer cell lines HCT-116 and HT-29 in addition to normal one 
NCM-460D were chosen for testing antiproliferative effect and cytotoxicity. HCT-116 
(ATCC-CCL-247) are adherent epithelial cells derived from colorectal cancer in an 
adult male; having a mutation at codon 13 of the proto-oncogene RAS. HT-29 (ATCC-
HTB-38) are adherent epithelial cells derived from colorectal cancer from a 44-year-old 
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adult Caucasian female; having a mutation at codon 273 of the p53 gene. NCM-460D 
(INCELL-2016) are normal adherent epithelial cells derived from the colon mucosa of 
a 68-year-old Hispanic male and used as a control. 
 
2.2.2. Antiproliferative and cytotoxic evaluation 
To evaluate the antineoplastic effect and safety of the formulation, the 
antiproliferative effect and cytotoxicity of the DZ-BAU2021-14N nanocrystals, as well 
as free drug, were assessed using 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay on colorectal cancer cell lines HCT-116 and HT-29 in addition to 
normal one NCM-460D.  
 
2.2.3.Medium and cell culture 
The cancerous cell lines HCT-116, HT-29 were seeded in Dulbecco's Modified 
Eagle Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) (Sigma), 1% penicillin and streptomycin (Sigma). NCM-460D non-tumorigenic 
cell lines were seeded in M3:BaseFTM culture medium (INCELL) supplemented with 
10% heat-inactivated fetal bovine serum (FBS) (Sigma), 1% penicillin and streptomycin 
(Sigma).  
 
2.2.4. Cell viability treatment and testing 
The culture of cell lines was carried out in flasks of 75 cm2. When the confluence 
reaches approximately 80%, the passage by trypsinization was carried out. Cells were 
washed with PBS-1X and then 2 ml of 1X trypsin (Lonza) were added. The cells were 
then incubated for 5 minutes at 37˚C to allow complete detachment. Suitable complete 
medium for each line was added to stop the action of trypsin. After centrifugation for 5 
minutes at 1000 rpm, cells were resuspended in an appropriate medium (table 1), diluted 
according to a specific factor, and then transferred to flasks containing 10 ml of the 
medium. The cells were incubated at 37˚C and 5% CO2, so that they reach confluence 
at 72 hours and were ready to use.  
 
2.2.4.1. Cell counting 
The Neubauer chamber was used to calculate the concentration of cells 
in a suspension. Each counting area was made up of 9 squares (0.1 cm × 0.1 
cm) and covered with a glass slide 0.01 cm above the surface of counting area. 
After detaching the Cells by trypsinization and centrifugation for 5 minutes at 
1000 rpm, cells were suspended in corresponding medium. An equivalent 
volume of cells and trypan blue were mixed and an aliquot was placed in the 
hemocytometer. The total number of cells was determined by dividing total 
number of white cells × 10000) by (number of squares counted × dilution). 
 
2.2.4.2. Preparation of study compounds  
Initial 12.5 mM solutions of test compound and its nanocrystals were 
prepared; DZ-BAU2021-14 in DMSO and stored at -20oC, while DZ-
BAU2021-14N in water and stored at 8oC. Water was used to prepare 
intermediate solutions of 1 mM concentration according to the formula C1 V1 
= C2 V2, and used to prepare the concentration range (10 µM, 20 µM, 40 µM 
and 50 µM) according to the same formula.  
 
2.2.4.3. Treatment and viability assay 
The MTT test was performed to study the antiproliferative effect of 
compounds. This colorimetric method is based on reduction of “yellow 
tetrazolium dye” 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) to blue-violet formazan crystals by metabolically active cell 
(Fig. 3). The amount of formazan produced is therefore proportional to the 
metabolic activity of viable cells and results were expressed as a percentage of 
viability compared to the controls treated with DMSO alone. 
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Fig.3: Metabolic conversion of MTT to formazan by viable cells  
  
After trypsinization, cells were counted, cultured, at a specific number 
and in a suitable medium (Table 1), in 96-wells plates and incubated for 24 
hours before their treatment, at 37oC and 5% CO2, so that they adhere and their 
confluence reaches 60%. 
 
Table 1:  Number of cells seeded per well and the corresponding medium. 
 
Cell line Number of cells per well Culture environment 
NCM-460D 12000 M3:BaseFTM 
HCT-116 7000 DMEM 
HT-29 7000 DMEM 
 
Cells were treated with different concentrations of DZ-BAU2021-14 
and DZ-BAU2021-14N (10 µM, 20 µM, 40 µM and 50 µM). A concentration 
of 0.4% DMSO was used in DZ-BAU2021-14 experiments after guaranteeing 
100% viability of cell lines with this concentration. After adding 10 µl of the 
MTT solution (5 g/L) (Sigma-Aldrich) to each well followed by a 3-hour 
incubation, the formed purple crystals were dissolved in 100 µl of stop solution 
(SDS 10% and HCl 1N) and left overnight. The color was then quantified using 
colorimetric assay by photon absorption spectrometry at a wavelength of 
595nm (ELISA Reader, multi-well scanning spectrophotometer). The MTT 
test was done at 24, 48 and 72 hours after cells treatment. Three to four trials 
of each experiment were affected and an average response was admitted. Dose 
response curves were plotted, graphs, Standard Deviation (SD) and Standard 
Error (±SE) were created and calculated using Microsoft Excel software (2016 
edition). Using GraphPad Prism 8 Software (San Diego, CA, USA), statistical 
significance comparing the treatment conditions with their controls was 
analyzed by two-way ANOVA with Dunnett's multiple comparisons test.  
 
2.2.4.4.Determination of the concentration inhibiting 50% of proliferation 
(IC50) 
IC50 values were calculated using GraphPad Prism 8 software after 
transforming the concentrations of compounds into log values and normalized 
the values of the effect of each concentration with 0% defined as the smallest 
mean in each data set and 100% defined as the largest mean in each data set. 
Statistical significance comparing treatment conditions between DZ-BAU2021-
14 and DZ-BAU2021-14N was analyzed by one-way ANOVA with Sidak's 
multiple comparisons test. A confidence level of P< 0.05 was considered 
statistically significant.  
 
3. RESULTS AND DISCUSSION 
 The promising antineoplastic pattern of DZ-BAU2021-14 against colorectal cancer cell lines 
HCT-116 and HT-29, and its minor cytotoxicity on non-tumorigenic NCM-460D (Kassem et al., 
2021), in addition to the significant role of nanocrystals in enhancing the efficacy of many drugs 
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directed the authors of the current study to extrapolate their anticipations to achieve better 
antiproliferative effects and cytotoxicity margins getting benefit of the lead DZ-BAU2021-14 
involving it in a nanocrystalline system. DZ-BAU2021-14 was reported to reveal low order of 
lipophilicity; 2.90-3.43 as estimated n-octanol/water partition coefficients and 3.16 Log Po/w, 
expecting optimal lipophilic behavior and poor to moderate water solubility (Kassem et al., 2020). 
This finding likewise encouraged the authors of this work to improve the physical properties of DZ-
BAU2021-14 trying to enhance its poor water solubility. 
 
3.1. Particle Characteristics 
3.1.1.Effect of the stabilizer concentration 
It was important to study the stabilizer concentration effect on nanocrystals 
characteristics. This was assessed by particle size, polydispersity index, and zeta 
potential. Using each stabilizer alone resulted in large particles with sizes 852 ± 134.15 
and 1229 ± 308.72 nm for Poloxamer and Cremophor respectively. However, using 
different ratios of Poloxamer: Cremophor (PLX : CRM) returned in different effects on 
particle size; using PLX : CRM ratio 1:1 resulted in remarkable particle size reduction 
compared to each stabilizer alone. On the other hand, PLX: CRM ratios of 1:2 and 2:1 
didn’t show advantage in particle size over the 1:1 ratio (Table 2). The use of Cremophor® 
RH 40 is essential due to its liability to achieve more stable nanocrystals (Madheswaran 
et al., 2014). Surfactants with high Hydrophilic-Lipophilic Balance (HLB) are considered 
good emulsifying ones, stabilizing the aqueous phase and reducing the size of particles 
(Kamel et al., 2009), hence, addition of the relatively hydrophilic Poloxamer 407 (HLB 
= 18) to Cremophor® RH 40 affected a reduction in particle size. In the current work, the 
combination of Poloxamer and Cremophor in 1:1 ratio provided the optimal nanocrystal 
size with 89.80 ± 11.2 nm, 0.18 ± 0.014, and -32.6 ± 0.50 mv as particle size, 
polydispersity index and zeta potential respectively (Table 2). 
 








3.1.2 Crystallinity analysis 
XRD patterns for DZ-BAU2021-14, nanocrystals DZ-BAU2021-14N and free 
nanocrystals are shown in figure 4. DZ-BAU2021-14 showed very strong characteristic 
diffraction peaks at 2𝜃 of 8.09˚, 8.40˚, 10.30˚, 10.50˚, 12.90˚, 14.15˚, 15.28˚, 17˚, 21.10˚, 
24.60˚, 25.90˚ and 27.16˚, indicating the pure crystalline status of the compound (Fig. 
4A). The principal peaks of pure DZ-BAU2021-14 were present in freeze-dried mixture 
DZ-BAU2021-14N but had lower intensity and were shifted down (Fig. 4B). This might 
be attributed to reduction in particle size. 
Ratio 







1:0 852±134.15 0.17± 0.029 -29.76±0.22 
0:1 1229±308.72 0.77±0.063 -11.20±0.84 
1:1 89.80±11.20 0.18±0.014 - 32.6±0.50 
1:2 218±15.73 0.82±0.1 -17.84±0.51 
2:1 167± 23.68 0.96±0.08 -27.20±0.30 
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Fig.4: X-ray diffraction (XRD) thermograms of DZ-BAU2021-14 (A), DZ-BAU2021-14N (B) 
and free nanocrystals (C). 
 
3.1.3. Fourier transform infrared spectroscopy (FT-IR) 
IR spectroscopic analysis provides information on chemical bonding, functional 
groups and presence or absence of changes in the crystalline structure of a compound. 
FT-IR spectrum of DZ-BAU2021-14 showed distinctive peaks at 3048 cm-1 (Aromatic, 
C-H stretching), 2970 cm-1 (C-H stretching), 1712 cm-1 (C=O stretching) and C-O-C 
stretching vibrations at 1066.42 cm-1 (Fig. 5A). FT-IR spectra of Poloxamer 407 and 
Cremophor® RH 40 showed characteristic bands of C-H stretching vibrations at 2883.13 
cm-1 and 2862.08 cm-1, O-H bending vibrations at 1341.90 cm-1 and 1359.42 cm-1, and 
C-O-C stretching vibrations at 1060.60 cm−1 and 1279.38 cm-1 (Fig. 5B). In contrast to 
pure DZ-BAU2021-14, the physical and freeze-dried mixtures showed characteristic C–
H stretching vibration bands of Poloxamer 407 and Cremophor® RH 40 in the functional 
group region at 2859 cm-1 and 2921cm-1 (Fig. 5(C, D)). There was no change in C–O–
O–C bending vibrations in physical and freeze-dried mixtures compared to free 
nanocrystals nevertheless, a decrease in intensity of the carbonyl stretching at 1712 cm-
1 was obvious in comparison to the free drug DZ-BAU2021-14 (Fig. 5).  This might 
suggest the presence of hydrogen bonding interactions at the interface between DZ-
BAU2021-14 and polymers where a variety of functional groups of different electronic 
environment provide high opportunities of hydrogen donors-acceptors challenges. The 
previous findings reflected the chemical stability of the founded nanocrystals.  
 
7
Kassem et al.: DZ-BAU2021-14N AS NOVEL PYRAZOLOPYRIDINE NANOCRYSTALS: APPRAISAL OF ANTICANCER ACTIVITY AGAINST HCT-116 AND HT-29 COLORECTAL CANCER CELL LINES





Fig.5: Fourier transform infrared spectroscopy (FT-IR) spectra of DZ-
BAU2021-14 (A), free nanocrystals (B), physical mixture (C) and DZ-
BAU2021-14N (D). 
 
3.1.4. Stability studies 
Formulation stability was assessed determining its physicochemical properties 
(particle size, PDI, and zeta potential) over the 3 months storage period at room 
temperature and at 4°C. Nanocrystals revealed no significant change in both particle 
size and PDI for 3 months at 4°C while particle size increased from 89.80 ± 11.20 to 
126.54 ± 13.54 nm after 3 months at room temperature manifesting Ostwald ripening 
phenomena that is hindered at low temperatures where redisposition of small particles 
is prevented, while at higher temperature ripening is observed due to fast redisposition 
of small particles into larger ones. 
3.2. In-Vitro Cytotoxicity Study 
 In the current work DZ-BAU2021-14 and DZ-BAU2021-14N exhibited differential anti-
proliferative responses on colorectal cancer cell lines (HCT-116, HT-29) and non-tumorigenic 
adherent epithelial cell line (NCM-460D). The stabilizers used to prepare nano-crystals were 
selected having minimal or no cytotoxicity; different types of Poloxamer were tested for their 
antiproliferative effects on different cancer cell lines and were reported having negligible 
cytotoxic effects (Subhashni D. Singh-Joy, 2008). Similarly, Cremophor was reported having 
minor reduction on cell viability in different cancer cell lines (Reinecke et al., 1997). 
3.2.1. Antiproliferative effect on HCT-116 
DZ-BAU2021-14 showed IC50 values of 27 and 19 µM compared to those of 
Roscovitine 12.24 and 14.6 µM on colorectal cancer cell lines HCT-116 and HT-29 
respectively (Table 3). 
Its fifty percent inhibitory concentration was 2-folds higher than that achieved by 
Roscovitine on HCT-116 cell line and was almost similar to that of Roscovitine on HT-
29. The treated colorectal cell lines HT-29, HCT-116 and NCM-460D showed different 
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Table 3: Percentage proliferation of HCT-116 and HT-29 treated with DZ-BAU2021-14 and DZ-
BAU2021-14N 
 
Compound HCT-116 HT-29 
10 µM 20 µM 40 µM 50 µM 10 µM 20 µM 40 µM 50 µM 
48 h 72 h 48 h 72 h 48 h 72 h 48 h 72 h IC502 48h 72 h 48 h 72 h 48 h 72 h 48 h 72 h IC502 
DZ-BAU2021-14 74 83 76 84 65 61 58 52 27 80 67 68 53 52 40 48 34 19 
St d1 17 19 12 9 20 28 14 22  9 7 9 15 3 16 4 10  
DZ-BAU2021-
14N 
86 71 78 62 62 44 58 42 22 92 83 88 72 88 61 76 83 40 
St d1 17 19 12 9 20 28 14 22  3 8 12 2 12 5 27 12  
Roscovitine         12.243         14.64 
1Standard deviations are related to three-four separate experiments, 2IC50 calculated after 72-hour exposure 
3Roscovitine reported IC20, IC50 and IC80 = 3.8 ± 0.45, 12.24 ± 1.17 and 39.4 ± 3.16 µM respectively on HCT-116 (Taha et al., 
2020) 







Fig.6: Dose response curves of DZ-BAU2021-14 and DZ-BAU2021-14N against NCM-
460D, HCT-116 and HT-29 
  
Percentage proliferation of HCT-116 has been remarkably inhibited in a dose-
time dependent manner at 10 µM, 20 µM, 40 µM and 50 µM of DZ-BAU2021-14 after 
48h (74 ± 9%, 76 ± 6%, 66 ± 10% and 58 ± 7%) and after 72h (83 ± 9%, 84 ± 5%, 61 ± 
14% and 52 ± 11%) respectively (Fig. 7). HCT-116 showed significant sensitivity 
towards DZ-BAU2021-14N in a dose-time dependent manner at 10 µM, 20 µM, 40 µM 
and 50 µM at 48h (86 ± 8%, 78 ± 7%, 62 ± 5%, and 58± 3%) and at 72h (71 ± 9%, 62 
± 8%, 45 ± 6% and 42 ± 4%) respectively (Table 3) (Fig. 7). DZ-BAU2021-14N 
demonstrated superior percentages inhibition on HCT-116 with an IC50 value of 22 µM 
compared to DZ-BAU2021-14 having IC50 of 27 µM (Table 3) (Fig. 8). This indicates 
that the fabrication of the DZ-BAU2021-14N nanocrystals enhanced its uptake by this 
specific HCT-116 cell line. 
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* P<0.05, **0.01<P<0.05, ***P<0.001, ****P<0.0001, P-values were calculated in respect to DMSO 
 




* P<0.05, **0.01<P<0.05, ***P<0.001, ****P<0.0001, P-values were calculated in respect to DZ-BAU2021-14 
 
Fig.8: Comparative antiproliferative effect between DZ-BAU2021-14 and DZ-BAU2021-
14N on HCT-116 
 
3.2.2.Antiproliferative effect on HT-29 
Figure 6 illustrated higher percentages of growth inhibition assigned to DZ-
BAU2021-14 against HT-29 compared to its activity against HCT-116. The percentage 
proliferation of HT-29 was significantly inhibited in dose-time dependent manner at 10 
µM, 20 µM, 40 µM and 50 µM by DZ-BAU2021-14 after 48h (80 ± 5%, 68 ± 4%, 52 ± 
2% and 48 ± 2%) and after 72h (67 ± 4%, 53 ± 9%, 40 ± 9%, and 34 ± 6%) respectively 
with an IC50 of 19 µM. In contrast, the percentage proliferation of HT-29 was 
significantly inhibited by DZ-BAU2021-14N at 50 µM after 24h (69 ± 10%) and at 40 
µM after 72h (64 ± 4%) with an IC50 of 40 µM (Table 3) (Fig. 9). In this context, it is 
necessary to report that DZ-BAU2021-14N didn’t reveal any advantage over DZ-
BAU2021-14, actually almost equal effects were observed at different concentrations for 
the first 24h, while HT-29 cell lines experienced more resistance towards DZ-BAU2021-
14N starting from day two (Fig. 10). These facts demonstrate that heterogeneity in cancer 
cell lines may result in differential responses to drug treatment. Additionally, the 
involvement of functional ester carbonyl groups in hydrogen bonding with stabilizer 
polymers deprives the pyrazolopyridine, DZ-BAU2021-14, from some of its anchoring 























































































P<0.05, **0.01<P<0.05, ***P<0.001, ****P<0.0001, P-values were calculated in respect to DMSO 




         * P<0.05, **0.01<P<0.05, ***P<0.001, ****P<0.0001, P-values were calculated in respect to DZ-BAU2021-14 
 
Fig.10: Comparative antiproliferative effect between DZ-BAU2021-14 and DZ-BAU2021-14N 
on HT-29 
3.2.3. Antiproliferative effect on NCM-460D 
Comparing cytotoxic potential of DZ-BAU2021-14 and DZ-BAU2021-
14N on normal cell lines NCM-460D, the normal cells showed resistance 
towards the pharmaceutically untreated DZ-BAU2021-14 that demonstrated 
slight inhibition of percentage proliferation ranging between 9% and 23% at 48h 
and 72h for 40 µM and 50 µM with an IC50 value of 200 µM (Fig. 11). The fact 
that ensures a safety profile covering the antiproliferative effect of DZ-
BAU2021-14. On the other hand, unfortunately DZ-BAU2021-14N has shown 
lower safety profile exhibiting significant inhibitory effect in a dose-time 
dependent manner at 10 µM, 20 µM, 40 µM and 50 µM after 48h and 72h on 
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Table 4: Percentage proliferation of NCM-460D treated with DZ-BAU2021-14 and DZ-
BAU2021-14N 
Compound NCM-460D 
10 µM 20 µM 40 µM 50 µM 
48 h 72 h 48 h 72 h 48 h 72 h 48 h 72 h IC502 
DZ-BAU2021-14 107 111 103 100 91 90 85 78 200 
St d1 17 19 12 9 20 28 14 22  
DZ-BAU2021-14N 83 59 73 57 53 42 60 38 33 
St d1 17 12 10 26 4 8 11 8  
1Standard deviations are related to three separate experiments 





* P<0.05, **0.01<P<0.05, ***P<0.001, ****P<0.0001, P-values were calculated in respect to DMSO 
 
 





* P<0.05, **0.01<P<0.05, ***P<0.001, ****P<0.0001, P-values were calculated in respect to DZ-BAU2021-14 
Fig.12: Comparative antiproliferative effect between DZ-BAU2021-14 and DZ-
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The obtained unanticipated results for the Nanocrystals DZ-BAU2021-14N 
towards different cell lines; namely the unsteady decreased antiproliferative effect on 
HT-29 and the increased cytotoxic on normal CRC, NCM-460D, can be related to 
abundant sets of possible explanations including permeability, transportation method, 
diffusion, integrity of cell membranes and others. In this respect, trying to find probable 
justification for different cellular responses towards the hydrophilic Nano formulation, 
the authors reviewed the colon adenoma carcinoma sequence. It was reported associated 
with alteration in cellular components one of which is lipid profile and lipid metabolism. 
Deregulation of lipid profile affects the synthesis of phospholipid cell membrane. This 
deregulation differs with individual variations and particular stages of CRC 
development (Hofmanová et al., 2020). This precipitates heterogeneity between cell 
lines and hence affects both structure and function of cellular phospholipid membranes 
resulting in different behaviors and responses including morphology, permeability, and 
uptake. The unexpected not satisfying finding will not limit the researchers but will 





 In the frame of applying pharmaceutical sciences in an interdisciplinary approach, the 
promising DZ-BAU2021-14 was incorporated in a stable nanocrystalline formulation aiming at 
enhancing its antiproliferative effect and minimizing its cytotoxic effect. The free drug and its 
nanoformulation were comparatively evaluated for their in-vitro anticancer activity.  DZ-BAU2021-
14 was proved to inhibit cell growth of both colorectal cancer cell lines HT-29 and HCT-116. HT-29 
was more sensitive towards DZ-BAU2021-14 compared to HCT-116, additionally, DZ-BAU2021-
14 was non-cytotoxic on normal cell line NCM-460D with only a slight inhibition at late time point 
and high concentration. DZ-BAU2021-14N exhibited higher percentages inhibition against HCT-116 
compared to HT-29 cells that were more resistant. On the other hand, DZ-BAU2021-14N affected 
NCM-460D at different concentrations and different time points. DZ-BAU2021-14 and DZ-
BAU2021-14N generally showed minor differences on both colorectal cancer cell lines indicating 
that DZ-BAU2021-14N offered non statistically significant advantage over the parental molecule DZ-
BAU2021-14. Although there was a non-statistically significant difference between DZ-BAU2021-
14N and the parental molecule, yet the nanoformulation improved water solubility for the drug and 
provided more specificity toward HCT-116 cell line. The drawback of compound nanocrystal 
cytotoxicity will be considered a challenge that requires further investigations and studies. 
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